Evidence map›Paper›PMID 42416732›Full record

ArticleRSC advances2026

Novel 4-formyl-1,3-phenylene-bisoxy-bis(methylene)-bis(1,2,3-triazole-

Shohreh Bakhshi Varzaneh, Mohammad Hosein Sayahi, Mohammad Halimi, Seyedeh Niloufar Ghafouri, Navid Dastyafteh, Somayeh Mojtabavi, Bagher Larijani, Maryam Mohammadi-Khanaposhtani, Mohammad Mahdavi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shohreh Bakhshi VarzanehDepartment of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
Mohammad Hosein SayahiDepartment of Chemistry, Payame Noor University Tehran Iran.
Mohammad HalimiDepartment of Biology, Babol Branch, Islamic Azad University Babol Iran.
Seyedeh Niloufar GhafouriSchool of Chemistry, College of Science, University of Tehran Tehran Iran.
Navid DastyaftehCenter for Research of Endemic Parasites of Iran, Tehran University of Medical Sciences Tehran Iran.
Somayeh MojtabaviDepartment of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences Tehran Iran.ORCID https://orcid.org/0000-0003-0584-5478
Bagher LarijaniEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.
Maryam Mohammadi-KhanaposhtaniCellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences Babol Iran maryammoha@gmail.com.ORCID https://orcid.org/0000-0001-7664-9664
Mohammad MahdaviEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences Tehran Iran momahdavi@tums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A series of thirteen new 4-formyl-1,3-phenylene-bisoxy-bis(methylene)-bis(1,2,3-triazole-

Identifiers

PMID42416732
PMCPMC13339992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.